The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Pre-clinical Development of Novel GCase Variants for Treating Parkinson’s Disease
Study Rationale: The most prevalent genetic risk factors for Parkinson’s Disease (PD) are mutations in GBA1, the gene that encodes the glucocerebrosidase (GCase) enzyme. Dysfunction of GCase leads to...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Evaluating Modifiable Risk Factors for Parkinson’s Disease in the Global Burden of Disease Study
Study Rationale: Parkinson’s disease is becoming more and more common over time, but we don’t know why. We will assess how much five key risk factors increase the risk of developing Parkinson’s...
-
Research Grant, 2025Investigating Aggregate-specific Alpha-synuclein Antibodies and Proximity Ligation Assay as Quantitative Biomarkers in Parkinson’s Disease
Study Rationale: Our new MJFR14-proximity ligation assay (PLA) technique has demonstrated an ability to detect disease-associated aggregates of alpha-synuclein in brain tissue previously considered...
-
Research Grant, 2025Modeling Parkinson’s Disease in Pre-clinical Models and Models Via Overexpression of Irregular-type and Mutant Alpha-synuclein
Study Rationale: Parkinson's disease is a serious brain condition that causes problems with movement and other body functions. Scientists know that a protein called alpha-synuclein builds up in the...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2025Dried Blood Spot PNPO Activity as a Biomarker for the Stratification of Parkinson's Disease
Study Rationale: Parkinson’s disease starts much earlier than the signs appear and people seek diagnosis. Scientists are therefore searching for changes that are relevant to the disease that could be...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Neuro-steroid Mediated Control of Sleep Co-morbidities in Parkinson's Disease
Study Rationale: Sleep disorders affect a large proportion of people with Parkinson’s disease (PD) and are often refractory to standard medications. Excessive daytime sleepiness (EDS), which is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.